Profile data is unavailable for this security.
About the company
Abbott Laboratories is a global healthcare company. The Company is engaged in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. The Diagnostic Products segment is engaged in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment is involved in the worldwide sales of a broad line of adult and pediatric nutritional products. The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products.
- Revenue in USD (TTM)40.73bn
- Net income in USD5.56bn
- Incorporated1900
- Employees114.00k
- LocationAbbott Laboratories100 Abbott Park Road, Abbot ParkABBOTT PARK 60064-3500United StatesUSA
- Phone+1 (224) 667-6100
- Websitehttps://www.abbott.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. | 3.78bn | 845.63m | 42.16bn | 11.00k | 50.78 | 26.74 | 43.63 | 11.14 | 10.09 | 10.09 | 45.15 | 19.16 | 1.20 | 3.87 | 6.85 | 344,072.80 | 26.91 | 28.00 | 39.47 | 43.49 | 60.41 | 58.74 | 22.34 | 21.35 | 1.03 | 51.05 | 0.3742 | 0.00 | 8.72 | 10.59 | 24.44 | 17.39 | 1.68 | -- |
| Cencora Inc | 283.83bn | 1.86bn | 46.21bn | 42.00k | 25.46 | 49.94 | 15.49 | 0.1628 | 9.21 | 9.21 | 1,407.82 | 4.70 | 4.44 | 15.60 | 11.97 | 6,757,877.00 | 2.91 | 0.9542 | 13.38 | 3.95 | 3.37 | 3.14 | 0.6556 | 0.2178 | 0.5476 | 14.76 | 0.8169 | 76.85 | 9.89 | 9.32 | 2.74 | 10.79 | 6.38 | 5.00 |
| Becton Dickinson and Co | 19.83bn | 1.46bn | 66.85bn | 73.00k | 46.12 | 2.58 | 17.84 | 3.37 | 5.01 | 4.86 | 67.99 | 89.50 | 0.3652 | 3.17 | 7.92 | 271,616.40 | 2.69 | 2.37 | 3.07 | 2.70 | 45.35 | 45.78 | 7.36 | 6.95 | 1.36 | 8.42 | 0.4276 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
| Medtronic PLC | 32.58bn | 3.93bn | 113.67bn | 95.00k | 29.81 | 2.37 | 17.25 | 3.49 | 2.97 | 2.97 | 24.66 | 37.39 | 0.3609 | 2.03 | 5.51 | 342,915.80 | 4.38 | 4.57 | 4.92 | 5.14 | 65.53 | 66.75 | 12.14 | 13.49 | 1.61 | 12.10 | 0.3665 | 80.58 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
| Boston Scientific Corporation | 15.23bn | 1.83bn | 121.52bn | 48.00k | 66.72 | 5.96 | 39.80 | 7.98 | 1.24 | 1.24 | 10.29 | 13.85 | 0.4307 | 1.94 | 6.72 | 317,250.00 | 5.16 | 2.50 | 6.07 | 2.91 | 69.08 | 68.84 | 11.98 | 6.47 | 1.14 | 5.73 | 0.339 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Stryker Corp | 21.39bn | 3.45bn | 138.67bn | 52.00k | 40.58 | 7.02 | 30.97 | 6.48 | 8.97 | 8.97 | 55.62 | 51.86 | 0.5589 | 1.60 | 6.22 | 411,326.90 | 9.01 | 6.60 | 10.94 | 7.84 | 64.05 | 63.99 | 16.12 | 13.13 | 0.9531 | -- | 0.3821 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Intuitive Surgical, Inc. | 7.57bn | 2.09bn | 171.44bn | 13.68k | 83.00 | 11.68 | 65.99 | 22.64 | 5.82 | 5.82 | 21.06 | 41.40 | 0.4957 | 2.10 | 7.52 | 553,707.30 | 13.81 | 12.42 | 15.42 | 13.83 | 66.86 | 67.60 | 27.86 | 26.31 | 4.22 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Danaher Corp | 23.57bn | 4.06bn | 196.78bn | 61.00k | 50.10 | 3.95 | 31.39 | 8.35 | 5.44 | 5.63 | 31.63 | 68.92 | 0.2884 | 3.29 | 6.23 | 386,360.70 | 4.96 | 5.93 | 5.47 | 6.56 | 59.16 | 58.79 | 17.21 | 19.11 | 1.04 | 17.19 | 0.2542 | 14.33 | -10.33 | 6.98 | -32.50 | 11.85 | 16.10 | 11.32 |
| Abbott Laboratories | 40.73bn | 5.56bn | 205.53bn | 114.00k | 37.17 | 5.23 | 23.35 | 5.05 | 3.18 | 3.18 | 23.29 | 22.60 | 0.5565 | 2.65 | 6.25 | 357,236.80 | 7.59 | 7.72 | 9.44 | 9.39 | 55.43 | 56.73 | 13.65 | 14.39 | 1.18 | 25.44 | 0.2716 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
| Thermo Fisher Scientific Inc | 42.35bn | 6.22bn | 233.20bn | 122.00k | 37.87 | 4.92 | 24.34 | 5.51 | 16.12 | 16.12 | 109.78 | 124.17 | 0.4397 | 4.62 | 4.48 | 347,098.40 | 6.50 | 7.79 | 7.66 | 9.11 | 40.76 | 44.94 | 14.79 | 16.76 | 1.37 | 22.89 | 0.4269 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 158.84m | 9.13% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 86.21m | 4.96% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 74.40m | 4.28% |
| Capital Research & Management Co. (International Investors)as of 30 Jun 2024 | 71.80m | 4.13% |
| Capital Research & Management Co. (Global Investors)as of 30 Jun 2024 | 57.24m | 3.29% |
| Geode Capital Management LLCas of 30 Jun 2024 | 34.41m | 1.98% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 24.87m | 1.43% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 20.36m | 1.17% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 19.35m | 1.11% |
| Polen Capital Management LLCas of 30 Jun 2024 | 15.31m | 0.88% |
